Michel Gatineau

Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial

J. Guigay, Anne Aupérin, Jérôme Fayette et al. · The Lancet Oncology · 2021 · 232 citations

Medicine, Oncology, Chemotherapy +14

Dosage Adjustment and Pharmacokinetic Profile of Irinotecan in Cancer Patients With Hepatic Dysfunction

Éric Raymond, Valérie Boige, Sandrine Faivre et al. · Journal of Clinical Oncology · 2002 · 118 citations

Pharmacy, Oncology, Pharmacology +17

Normal serum neuron specific enolase (NSE) value after the first cycle of chemotherapy

Karim Fizazi, I. Cojean, Jean‐Pierre Pignon et al. · Cancer · 1998 · 67 citations · Full text

Medicine, Oncology, Chemotherapy +12

Phase 2 trial comparing sorafenib, pravastatin, their combination or supportive care in HCC with Child–Pugh B cirrhosis

Jean‐Frédéric Blanc, Faïza Khemissa, Jean–Pierre Bronowicki et al. · Hepatology International · 2021 · 49 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +12

A phase I and pharmacokinetic study of the novel aza-anthracenedione compound BBR 2778 in patients with advanced solid malignancies.

Sandrine Faivre, Éric Raymond, Valérie Boige et al. · PubMed · 2001 · 37 citations

Medicine, Oncology, Pharmacology +12